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Colchicine has been effectively used in the treatment of several inflammatory conditions, such as gouty attacks, serositis related to familial
Mediterranean fever, Behc¸et syndrome, and more recently also in acute and recurrent pericarditis. Growing evidence has shown that the
drug may be useful to treat an acute attack and may be a way to cope with the prevention of pericarditis in acute and recurrent cases
and after cardiac surgery. Nevertheless, clinicians are often sceptical about the efficacy of the drug, and concerns have risen on possible
side effects and tolerability. In this review, we analyse current evidence to support the use of the drug, as well as possible harms and
risks related to drug interactions, reaching the conclusion that colchicine is safe and useful in recurrent pericarditis, if specific precautions
are followed, although less evidence supports its use for the treatment of acute pericarditis, where colchicine remains optional and there is a
need for further multicentre confirmatory studies. This paper also reviews specific dosing and precautions for the clinical use.
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Background
Colchicine is a potentially poisonous natural product and second-
ary metabolite, originally extracted from plants of the genus
Colchicum (Autumn crocus, Colchicum autumnale, also known as
the ‘meadow saffron’). Its name comes from Colchis or Kolchis
(Greek: Kolxı´6, Kolchı´s), an ancient Georgian state and
kingdom, on the eastern shore of the Black Sea, where plants
were widespread. The first medical use of the bulbs of the
meadow saffron has been reported in the first century AD. Colchi-
cum extracts were first described as a treatment for gout in De
Materia Medica by Pedanius Dioscorides in the first century AD.
Colchicine was first isolated in 1820 by the two French chemists
P.S. Pelletier and J. Caventon. Originally used to treat rheumatic
complaints and especially gouty attacks, it was also prescribed
for its cathartic and emetic effects.
Colchicine may be extracted also from Gloriosa superba
(Figure 1). All parts of this plant contain colchicine and related alka-
loids and are therefore dangerously toxic if ingested, especially the
tubers; contact with the stems and leaves can cause skin irritation.
However, various preparations of the plant are used in traditional
medicines for a variety of complaints in both Africa and India.
Although the well-known and official indication for the treat-
ment and prevention of gouty attacks,1 colchicine has been
studied and prescribed for the treatment and prevention of
other inflammatory conditions (i.e. serositis in familial Mediterra-
nean fever—FMF) (Table 1).2 More recently, the use of colchicine
has been proposed for the treatment and prevention of pericardi-
tis. Following the successful use of the drug in the treatment and
prevention of polyserositis related to the FMF, Bayes de Luna
and co-workers proposed the use of the drug for recurrent peri-
carditis for the first time in 1987.3
Following this initial experience, a number of retrospective
studies have been published supporting the use of colchicine in
recurrent cases (Table 2).4,5 –8 The main study limitations of
these papers are related either to the retrospective design with
the lack of a control group, or to the small sample size. The
largest experience is a multicentre retrospective study of 51
patients with recurrences, where only 7 of 51 patients (13.7%) pre-
sented with new recurrences during 1004 patient-months of col-
chicine treatment.4 In a recent retrospective multicentre
analysis,9 where published and unpublished cases treated with col-
chicine after at least two relapses were aggregated, only 21 of 119
patients (17.6%) presented with new recurrences under colchicine
treatment, and 30% after its discontinuation.
On the basis of cumulative anecdotal evidence, observational
studies on recurrent pericarditis, and expert consensus, colchicine
has been recommended in the treatment of recurrent pericarditis
(class I recommendation in the 2004 guidelines of the European
Society of Cardiology), and considered optional, but probably
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useful in acute pericarditis (class IIa recommendation in European
guidelines).10 In the guidelines, the recommended dose is 2 mg/day
for 1–2 days, followed by a maintenance dose of 1 mg/day.
However, several authors recommend that colchicine should be
administered to patients with two or more relapses, and thus
only after the failure of conventional treatment.11,12
Growing evidence suggests that early use of colchicine may be
beneficial. The strongest evidence to support the use of the drug
in recurrent pericarditis comes from an open-label clinical trial
(CORE), where colchicine, as adjunct to conventional treatment,
significantly decreased the subsequent recurrence rate (actuarial
rates at 18 months were, respectively, 24.0 vs. 50.6%, P ¼ 0.022;
NNT ¼ 4.0; 95% CI 2.5–7.1) and symptoms persistence at 72 h
(respectively 9.5 vs. 31.0%; P ¼ 0.029) in 84 patients with a first
recurrence.13
Weak evidence has been reported to support the use of colchi-
cine for acute pericarditis (first attack) before 2005. A preliminary
small French study without a control group14 tested the use of
colchicine in 19 patients with a first episode of acute pericarditis.
After a mean follow-up of 5 months, a recurrence rate of 10.5%
was found. In the recently published open-label clinical trial
(COPE), colchicine, as adjunct to conventional treatment, signifi-
cantly decreased the subsequent recurrence rate (actuarial rates
at 18 months were, respectively, 10.7 vs. 32.3%, P ¼ 0.004;
NNT ¼ 5.0) and symptoms persistence at 72 h (respectively 11.7
vs. 36.7%; P ¼ 0.003) in 120 patients with a first episode of
acute pericarditis.15 Colchicine was discontinued in five patients
(8.3%) because of diarrhoea.
In both trials (CORE and COPE), which represent the first ran-
domized studies on the management of pericarditis, a maintenance
dose of 0.5 mg twice daily was adopted, and reduced to 0.5 mg
daily in patients ,70 kg, thus lower doses may be equally effica-
cious but with a possible lower rate of side effects. The available
evidence for the recommended duration of treatment in acute
(3 months) and recurrent pericarditis (6 months) is based on
data from first observational studies in acute and recurrent pericar-
ditis,3–8,14 and the more recent COPE and CORE trials.13,15 In
recurrent more severe cases, some authors advocate a longer
use of the drug up to 12–24 months after the last recurrence, tai-
lored to the single patient and with a gradual tapering,4,12 consid-
ering also that recurrences have been described after colchicine
discontinuation.9,12
In pericarditis, a sustained anti-inflammatory effect may be ben-
eficial in autoimmune (autoreactive) forms, but it is still unclear if it
may delay the clearance of an infectious agent in other cases. This
does not seem the case in the COPE trial, but further evidence is
needed before routine use of the drug can be recommended in
acute pericarditis.
On the contrary, the drug has been shown not to be efficacious
in chronic pericardial effusion and when there is no evidence of
inflammation (i.e. cases with negative C-reactive protein).4,12,16,17
Mechanism of action
Three major interactions of colchicine with specific proteins
modulate its pharmacokinetics: tubulin, cytochrome P450 3A4
(CYP3A4), and P-glycoprotein. Tubulin is ubiquitous and the
main colchicine-binding protein. Cytochrome P450 3A4 is mainly
Figure 1 Colchicine can be extracted from two plants of the
lily family: Colchicum autumnale (meadow saffron) and Gloriosa
superba (glory lily).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 More common indications and dosing of colchicine
Indication Dosing
Gouty arthritis
Prophylaxis Oral: 0.5–0.6 mg twice daily
Acute attack Oral: 0.5–1.2 mg (initial) followed by 0.5–0.6 mg every 1–2 h (maximum dose 3–6 mg)
FMF (unlabelled)
Prophylaxis Oral: 1–2 mg daily in divided doses
Primary biliary cirrhosis (unlabelled) Oral: 0.5–0.6 mg twice daily
Pericarditis (unlabelled) Oral: 0.5–0.6 mg twice daily
In some European countries, colchicine is available only as 1 mg tablets and a single dose is generally 0.5 or 1.0 mg; for dose adjustments, see Table 3; dosing may be reduced to
0.5–0.6 mg/day in patients at risk of toxicity or intolerant.
FMF, familial Mediterranean fever.
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found in the intestine and liver, and it is involved in the metabolism
of many drugs. Cytochrome P450 3A4 metabolizes colchicine in
the liver. P-glycoprotein is an ATP-dependent phosphor-
glycoprotein located in the cell membrane and responsible for
the excretion of the drug in the intestine, liver, kidney, and
blood–brain barrier (Figure 2). Different expression and activity
of CYP3A4 and P-glycoprotein may be responsible for the wide
interindividual response to the drug. Both proteins are also sub-
strate for different drugs, with possible pharmacological
interactions that may affect colchicine pharmacokinetics.18
The onset of the action of colchicine when orally administered is
relatively rapid with pain relief achievable within 12–24 h if ade-
quately dosed. Colchicine is promptly absorbed by the jejunum
and ileum with a considerable interindividual variability. Although
the drug is lipophilic, colchicine is partly blocked by the intestinal
barrier with a mean bioavailability of 45% (24–88%) in healthy sub-
jects.19 This variable bioavailability may explain potential different
interindividual responses to the same dose of the drug according
to different enterocyte CYP3A4-metabolism and P-glycoprotein
excretion. Peak serum concentration is reached within 0.5–2 h
after oral administration, then concentration declines for the
next 2 h before increasing again owing to enterohepatic recycling.
Thus, administration twice daily is able to reach better clinical
results, also improving drug tolerability. The drug is able to con-
centrate in leucocytes, where it exerts marked effects, altering
adhesion, mobility, and cytokine production. These actions
explain most of the inflammatory effects of colchicine, giving rise
to several therapeutic uses. However, the accumulation in leuco-
cytes is slow with a peak intracellular concentration after 48 h
from a 1 mg oral dose in healthy subjects. The biological effects
require 24–48 h to develop, and, when the drug is discontinued,
colchicine declines with an elimination half-life of 16 h. Thus, bio-
logical effects decline after 24–48 h in white blood cells.20
The protein binding is between 10 and 31%. The drug is partially
metabolized in the liver by de-acetylation with a half-life elimin-
ation of 12–30 min, which is prolonged to 45 min in end-stage
renal disease. Colchicine and its metabolites are eliminated by
the kidneys and bile. Decreased clearance through either of
these two pathways increases the risk of side effects and poisoning.
However, the kidneys contribute only 10–20% of colchicine clear-
ance, and hepatic clearance is the main determinant of colchicine
accumulation.2,21,22 Although colchicine may enter all tissues in
the body, P-glycoprotein expression limits the cellular exposition
to colchicine in several physiological barriers (i.e. placenta,
blood–brain barrier). Nevertheless, P-glycoprotein saturation by
other drugs may increase the levels of colchicine, impairing its
excretion. Also, colchicine enters breast milk.2,23,24
The exact mechanism of colchicine action is not fully under-
stood. Most of the pharmacological effects of colchicine on cells
involved in inflammation appear to be related to the capacity of
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Main published studies on the treatment of recurrent pericarditis by colchicine
Study Year Design Patients Maintenance dose (mg/day) Adjunct to standard therapy Follow-up (months) Recurrence rate
Guindo et al.5 1990 NR 9 1.0 Yes 10–54 0/9 (0.0%)
Adler et al.6 1994 NR 8 1.0 Yes 18–34 0/8 (0.0%)
Millaire et al.7 1994 NR 19 1.0 No 32–44 4/19 (21.0%)
Adler et al.4 1998 NR 51 1.0 Yes 6–128 7/51 (13.7%)
Imazio et al.8 2005 NR 35 1.0 Yes 48–108 3/35 (8.6%)
CORE13 2005 R 84 0.5–1.0 Yes 8–44 9/42 (21.0%)
Recurrence rate in patients treated with colchicine.
Year, publication year; NR, not randomized, observational; R, randomized trial.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Colchicine dose adjustment according to age and renal or hepatic dysfunction
Condition Dose adjustment
Children
5 years 0.5 mg/day
.5 years 1.0–1.5 mg/day in two to three divided doses
Elderly (.70 years) Reduce dose by 50%
Renal impairment
Clcr 35–49 mL/min 0.5–0.6 mg once daily
Clcr 10–34 mL/min 0.5–0.6 mg every 2–3 days
Clcr ,10 mL/min Avoid chronic use of colchicine. Use in serious renal impairment is contraindicated by the manufacturer
Hepatic dysfunction Avoid in severe hepatobiliary dysfunction and in patients with hepatic disease
M. Imazio et al.534
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colchicine to inhibit the process of microtubule self-assembly by
binding b-tubulin with the formation of tubulin–colchicine com-
plexes, thus interfering with several cellular functions (such as
chemotaxis, degranulation, phagocytosis) (Figure 3).2,4,23,24 On
this basis, colchicine decreases leucocyte motility and phagocyto-
sis, thereby reducing the inflammatory response. Colchicine
Figure 2 Role of cytochrome P450 3A4 and P-glycoprotein in metabolism and transport of colchicine (see text for details). Clb, biliary clear-
ance; Clr, renal clearance; P-Gly, P-glycoprotein.
Figure 3 Anti-inflammatory mechanism of colchicine (see text for details).
Colchicine for pericarditis 535
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shows a preferential concentration in leucocytes, and the peak
concentration of colchicine may be more than 16 times the peak
concentration in plasma.4 This effect seems to explain therapeutic
effects at low oral doses.13,15
Safety and side effects
At doses of 1–2 mg per day, colchicine is safe even when given
continuously over decades.25,26 Available data on the dose-
dependency of colchicine effects come from cases with acute poi-
soning. Ingested doses ,0.5 mg/kg cause gastrointestinal symp-
toms and clotting factors deficits. Doses ranging from 0.5 to
0.8 mg/kg induce bone marrow failure and carry a 10% mortality.
Death follows ingestion of .0.8 mg/kg. Therapeutic doses range
from 0.015 to 0.030 mg/kg with a small therapeutic margin. The
narrow therapeutic margin is a source of concern for the physician,
but careful dosing may ensure safe use of the drug.
Colchicine therapeutic effects are related to leucocytes concen-
tration of the drug rather than plasma levels; nevertheless, plasma
levels may be useful to detect low intestinal absorption, risk of tox-
icity, and poor compliance. Although there are no available studies
that precisely established the therapeutic plasma levels of colchi-
cine, plasma levels between 0.5 and 3 ng/mL correspond to clinical
therapeutic effects. Assays should be done at least 8 h after the last
dose and are best when performed immediately before the next
dose. Wide interindividual colchicine bioavailability may explain
different individual susceptibility to the effects of the drug. Lower
plasma levels have been detected in non-responders in patients
with FMF. Individual differences in colchicine plasma levels may
reflect differences in the intestinal absorption, which is dependent
on different expression of P-glycoprotein and CYP3A4.
Serious safety concerns have been associated with intravenous col-
chicine use; 50 reports of serious adverse events have been reported,
including 23 deaths (through June 2007).27 Three of these deaths were
associated with the use of an improperly compounded intravenous
colchicine used to treat chronic back pain—not an accepted practice.
In February 2008, the FDA ordered companies to stop manufacturing
injectable colchicine within 30 days and to stop shipping the product
within 180 days. After these dates, all injectable colchicine products
must have FDA approval in order to be manufactured or shipped.
Injectable colchicine has a narrow therapeutic index and most
related toxicities are dose-related. Recently (October 2007), the
only manufacturer of injectable colchicine voluntarily discontinued
production. The FDA also strongly discourages the compounding of
injectable colchicine owing to serious safety risks. Oral colchicine
tablets are not affected by this action. At present, only oral use is rec-
ommended, although there are no data on other route of adminis-
tration (i.e. intrapericardial), and on the possibility to detect
colchicine in pericardial tissue or fluid.
Usual side effects are gastrointestinal (up to 10–15% of cases)
including nausea, vomiting, diarrhoea, abdominal pain, usually limit-
ing drug compliance and being a common cause of drug withdra-
wal2,4,13,15; although generally mild, they may resolve with dose
reduction. Weight-adjusted doses, such as in the COPE and
CORE trials, may halve these side effects.13,15 Other common
side effects at higher doses include other gastrointestinal side
effects with anorexia, elevation of transaminases, and alopecia
(1–10%). In ,1% of cases, other side effects are reported, includ-
ing agranulocytosis, aplastic anaemia, bone marrow suppression,
hepatotoxicity, and myotoxicity.2,4,15,23,24
Colchicine inhibition of cell division has raised concern about
the possible adverse effects in patients treated prior to conception,
during pregnancy or breast-feeding, or during childhood. Although
azoospermia has been reported as a rare possible side effect
(,1%), no interference of colchicine treatment was recorded in
either growth rate or fertility after a cumulative 15 000 years of
follow-up in patients with FMF.25,26 In these patients, even pro-
longed exposure to colchicine seems to have no effects on male
or female fertility, pregnancy outcomes, foetal development or
development after birth.28
However, in a general population, contraindications include
hypersensitivity to colchicine or any component of the formu-
lation, severe renal, gastrointestinal, hepatic, or cardiac disorders,
blood dyscrasias, pregnancy.13,15
Dose reduction should be considered in patients who develop gas-
trointestinal symptoms (anorexia, diarrhoea, nausea, vomiting) or
weakness related to drug therapy. Dose adjustment is necessary
also for patients with renal impairment, debilitated patients, and the
elderly (Table 3). Moreover, monitoring is recommended during
therapy with colchicine (blood cell count, transaminase, CK, and
renal function test at least at baseline, and after 1month of treatment).
During oral administration of colchicine, the drug may induce
reduced absorption of vitamin B12 and rarely may result in macro-
cytic anaemia or neurological dysfunction. Supplement with
vitamin B12 may be considered in special patients subsets.
23
Drug interactions
Colchicine undergoes intensive hepatic metabolism (CYP 3A4).
Consequently, drugs that interact with the cytocrome P-450
system may interfere with colchicine, increasing the levels/effects
of colchicine (Table 4). CYP3A4 inhibitors (azole antifungals,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Major drug interaction with colchicine
Drug Type Remedy
Cyclosporine Reciprocal enhancement of
adverse/toxic effects
Consider therapy
modification
CYP3A4 inhibitors May increase levels/effects
of colchicine
Monitor therapy
HMG-CoA
reductase
inhibitors
Increased risk of
myotoxicity
Consider therapy
modification
Macrolide
antibiotics
Decrease colchicine
metabolism
Consider therapy
modification
Verapamil Increase verapamil serum
concentration, enhance
colchicine nephrotoxicity
Monitor therapy
A patient-specific assessment must be conducted to determine whether the
benefits of concomitant therapy outweigh the risks. Specific actions must be taken
in order to realize the benefits and/or minimize the toxicity resulting from
concomitant use of the agents. These actions may include aggressive monitoring,
empiric dosage changes, choosing alternative agents.
M. Imazio et al.536
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diclofenac, doxycycline, imatinib, isoniazid, nefazodone, nicardipine,
propofol, protease inhibitors, quinidine, telithromycin, and verapa-
mil) may increase toxicity of colchicine.29 Cyclosporine may also
increase toxicity of colchicine. On the other hand, colchicine
may increase the serum concentration of cyclosporine. Nephro-
toxicity, hepatotoxicity, and the risk of myopathies may also be
increased.30–32
As mentioned, colchicine is also a substrate of P-glycoprotein, a
transporter involved in the elimination of several drugs. Macrolides
are inhibitors of P-glycoprotein and cytochrome P450-dependent
enzymes and may decrease colchicine excretion. Co-administration
of colchicine and macrolides may impair colchicine elimination,
resulting in possible drug excess and toxicity particularly in the
elderly and/or with renal impairment.33–35 At present, it seems
reasonable to avoid the co-administration of colchicine and macro-
lides, as well as the use of the drug in patients with hepatobiliary dys-
function, severe renal, gastrointestinal disorders, and blood
dyscrasias. It is also prudent to reduce maintenance/prophylactic
dose by 50% in individuals .70 years and in patients with impaired
renal function with glomerular filtration rates ,50 mL/min
(Table 3). Caution is recommended in the use of colchicine in patients
with hepatobiliary dysfunction since biliary excretion is the main
route of colchicine elimination; the risk of colchicine poisoning is
increased in patients with liver diseases such as primary biliary cirrho-
sis or other forms of cirrhosis.21,22 On the other hand, in a cohort of
58 patients with pericarditis,12 5 patients (8.6%) presented with
abnormal liver tests in the first attack. However, these abnormalities
were related to the viral infection and disappeared with the resol-
ution of the attacks. So, this potentially useful therapy may be con-
sidered in patients with abnormalities in liver tests caused by the
systemic disease itself.29 Dose adjustment may be considered using
halved doses in mild-to-moderate liver dysfunction. Severe liver dys-
function is usually considered a contraindication.
An additional interaction is that with HMG-CoA reductase
inhibitors (statins). Colchicine may enhance the myopathic (rhab-
domyolysis) effect of HMG-CoA reductase inhibitors. Also, it
may increase the serum concentration of HMG-CoA reductase
inhibitors. At least 9 case reports describe patients in whom myo-
toxicity, ranging from weakness and myopathy to fatal rhabdomyo-
lysis, developed following the initiation of combination therapy
involving colchicine and an HMG-CoA reductase inhibitor
(statin).36–44 Reported cases have involved simvastatin,36–39
atorvastatin,40,41 fluvastatin,42 lovastatin,43 and pravastatin.44
Although no clear underlying patient risk factors (other than the
colchicine–statin association) were present in all cases, several
of the patients had at least mildly impared renal function,36,38–
40,44 and two were transplant recipients receiving other potentially
interacting drugs (i.e. cyclosporine).37,41 In most of the cases,
muscle weakness was the initial symptom, and the initial onset of
symptoms was 2–3 weeks (but as long as several months) after
the initiation of the combination. The precise mechanism of this
interaction is unclear, but it may have pharmacodynamic and/or
pharmacokinetic components. Colchicine and statins have each
been independently associated with myotoxicity; in one review
of 475 patients hospitalized for rhabdomyolysis, statins and colchi-
cine were among the prescription agents most commonly
involved.45 In addition, colchicine and many of the statins (lovasta-
tin, simvastatin, atorvastatin) are metabolized to a substantial
degree by CYP3A4,46 with some in vitro evidence suggesting colchi-
cine may inhibit CYP3A4 to some degree.47 These data suggest
that at least for some statins, colchicine could increase statin con-
centrations, further increasing the risk of myotoxicity. Further, col-
chicine may impair the excretion of some statins via the inhibition
of organic anion transport, an effect that has been demonstrated in
vitro with pravastatin.48 This action would also lead to increased
statin concentrations and increased risk of toxicity.
Thus, it is recommended to carefully monitor for signs of muscle
pain and/or weakness with concomitant therapy. Although this is
advised with monotherapy involving either agent (since each can inde-
pendently causemuscle toxicity), it is especially prudent when using in
combination. On this basis, every patient should undergo a careful
monitoring of possible side effects also including blood analyses (at
least transaminases, serum creatinine, CK, and blood cell count)
before starting the drug, and later at least after 1 month of treatment.
Future research and ongoing
clinical trials
At present, double-blind randomized trials are lacking to guide the
evaluation and management of pericarditis, and strategies to
prevent recurrences require further investigations.
Results from prospective, randomized, open-label studies suggest
that colchicine, as adjunct to conventional therapy, might be a first-line
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Ongoing multicentre, double-blind randomized trials on the use of colchicine in the treatment and prevention
of pericarditis
Trial Patients to enrol Treatment arms Primary endpoint
COPPS49 360 patients after cardiac surgery Placebo vs. colchicine (primary prevention of PPS) PPS at 12 months
ICAP50 240 patients with acute pericarditis Conventional treatment plus placebo vs.
conventional treatment plus colchicine
Recurrence rate at 18 months
CORP51 120 patients with first recurrence Conventional treatment plus placebo vs.
conventional treatment plus colchicine
Recurrence rate at 18 months
CORP 251 240 patients with the second or
subsequent recurrence
Conventional treatment plus placebo vs.
conventional treatment plus colchicine
Recurrence rate at 18 months
COPPS, COlchine for the Prevention of the PostPericardiotomy Syndrome; ICAP, Investigation on Colchicine in Acute Pericarditis; CORP, Colchicine for Recurrent Pericarditis.
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drug either in the treatment of acute pericarditis or in recurrent peri-
carditis. However, further studies are required to validate the use of
colchicine for pericarditis. Ongoing multicentre, double-blind ran-
domized trials (Table 5) will provide a stronger evidence-base for or
against the routine use of colchicine in pericarditis.49–51
Increasing data have expanded our knowledge on colchicine
pharmacology, and now, pharmacogenomic considerations may
explain interindividual variability in the response to the drug. It is
well known that 5–10% of patients with FMF do not respond to
colchicine. Different polymorphisms of P-glycoprotein may
explain some of these cases of colchicine resistance.52,53 In the
future, a better understanding and characterization of these
polymorphisms may aid also in the identification of responders
and non-responders also in cases of pericarditis not associated
to FMF.
Conclusions
Although clinicians are often sceptical on the possible use of
colchicine in pericarditis, growing evidence suggests that the drug
may be useful in patients with recurrent pericarditis. Common
reasons of scepticism include finding of further recurrences on
treatment, colchicine failure as monotherapy (efficacy demon-
strated almost exclusively for combination therapy with a non-
steroidal anti-inflammatory drug—NSAID or corticosteroids),
and the need for drug withdrawal owing to gastrointestinal
intolerance. Nevertheless, colchicine may halve recurrence when
used as adjunct to aspirin, an NSAID or corticosteroids, as in
the CORE trial; thus, patients on colchicine may still have recur-
rences, but they are generally less intense and longer with an
improved quality of life and a reduced overall burden of the
disease. Practical tips to improve drug compliance may be using
appropriate weight-adjusted doses and starting from lower doses
without a loading dose, then increasing the dose if tolerated
(Table 6).
The choice of treatments for pericarditis should take into
account the prognosis, favouring fewer toxic and less expensive
drugs,11,12,54–56 especially in recurrent cases, where new treat-
ments are often searched. Compared with other drug treat-
ments, colchicine appears to be one of the cheapest (daily
cost of $0.23 in the USA, and E0.13 in western Europe) and
safer available treatment if a careful selection and monitoring
of patients is followed. The natural history of the disease is
characterized by a very active initial phase followed by a late
dormant phase with less and less recurrences till a stable remis-
sion after an unpredictable time.12,56 Drug treatment (above all
colchicine) may hasten the progression towards the late
dormant phase, reducing recurrence rate and, thus, improving
the quality of life.
Conflict of interest: none declared.
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